Peptide Blood Work: Which Labs a Label Requires and Which Are Sold as a Package

Whether a peptide comes with required blood work depends on whether it has an FDA label. Tesamorelin (Egrifta) does, and its label tells prescribers to check IGF-1 during treatment and glucose before and during it.^[1] The GLP-1 drugs ask for much less: blood glucose in people with diabetes and kidney tests if vomiting or diarrhea threatens dehydration.^[2][3] BPC-157, TB-500, MOTS-c and the other peptides covered by the October 2026 HHS policy have no label, so no monitoring rule exists for them. Any panel a clinic orders is the prescriber’s own judgment. The policy itself asks for something else: that pharmacies report serious adverse events and quality problems to FDA’s MedWatch.^[5] Patients can file those reports too.^[6]

Three places a monitoring rule can come from

A lab test attached to a peptide traces back to one of three sources. The first is the FDA label. When a drug is approved, its prescribing information spells out what to check, when, and what to do with an abnormal result, based on what showed up in the trials. The second is clinical judgment, which is what a doctor orders because of your history, your other medicines or a symptom. It can be sound, and it differs from one prescriber to the next. The third is regulation. The HHS policy that opened a compounding route for six peptides sets conditions on the pharmacy and the product; it puts no testing requirement on the patient.^[5]

Clinic marketing tends to blur the three, so that a broad panel sold as part of a membership sounds as though a label required it. Knowing which source a test comes from tells you how much weight to give it, and whether skipping it means skipping a safety step or just an upsell.

What the approved peptide labels say to check

Tesamorelin carries the most specific instructions, and the reason is in its trial data. It raises growth hormone and, through it, IGF-1. After 26 weeks, 47% of patients had IGF-1 more than two standard deviations above normal and 36% were more than three above it. The label calls the effects of long-running IGF-1 elevations “unknown,” tells prescribers to monitor IGF-1, and suggests stopping in people with persistent elevations, particularly if the drug is not working well.^[1] Diabetes (an HbA1c of 6.5% or higher) developed in 5% of patients on the drug and 1% on placebo, which is why glucose is checked before the first dose and periodically after.^[1] The label also rules the drug out in people with active cancer, pituitary damage or pregnancy.^[1] Our tesamorelin profile covers who it is approved for, and tesamorelin for weight loss covers its off-label use.

The GLP-1 labels list no routine blood work for everyone. Glucose monitoring applies to people with diabetes, kidney tests are triggered by vomiting or diarrhea that could dehydrate, and eye checks apply to people who already have diabetic retinopathy.^[2][3] Both labels go further on one test and advise against relying on it. Routine calcitonin checks or thyroid ultrasound are “of uncertain value” for catching the rare thyroid cancer in the boxed warning, and such monitoring “may increase the risk of unnecessary procedures.”^[2][3] That is FDA’s own labeling acknowledging that an extra test can do harm. Bremelanotide (Vyleesi), a peptide approved for low sexual desire in premenopausal women, names no blood test at all; its label asks prescribers to make sure blood pressure is well controlled before and during treatment.^[4] Our GLP-1 lab monitoring cheat sheet sets out a reasonable baseline and the tests not worth ordering, and protein targets and the lab panel covers the nutrient tests suggested during weight loss.

Sermorelin and IGF-1: a habit without a current label

Sermorelin is the case people ask about most, because clinics nearly always pair it with an IGF-1 test. It was once an approved drug, sold as Geref; FDA’s database lists both Geref applications as discontinued, and DailyMed holds no sermorelin label today.^[8] So there is no current prescribing information telling anyone what to monitor. IGF-1 checks on sermorelin come from prescriber practice and from the logic of how it works: it prompts the pituitary to release growth hormone, and IGF-1 is the steadier blood marker of that hormone. Our sermorelin profile covers the rest.

The published data show why a single IGF-1 number is a blunt tool. In a 1997 Johns Hopkins study, 11 healthy men aged 64 to 76 with low IGF-1 injected GHRH 1-29, the hormone fragment sermorelin is based on, every night for six weeks. Their nighttime growth hormone rose, but IGF-1 did not change.^[9] In a 2017 chart review of men on testosterone, IGF-1 rose from about 160 to 239 ng/mL, but those men took sermorelin together with two other growth hormone releasing peptides, and only 14 of 105 records met the study’s criteria.^[10] Neither study tells you what IGF-1 level is safe to sustain. The tesamorelin label states plainly that no one knows the effect of prolonged elevations.^[1]

A 2026 review of growth hormone peptides sold online, from the endocrinology department at Poznań University of Medical Sciences, lists the adverse effects reported in users: changes in prolactin and cortisol, blood sugar disturbances, fluid retention and joint pain. The authors wrote that clinicians increasingly need a framework “to interpret symptoms and laboratory abnormalities” in these patients, and offered one without endorsing the regimens.^[11] That is a fair description of what blood work on an unapproved growth hormone peptide can do. It can catch some problems. It cannot show that the product is safe.

The six HHS-policy peptides: no label, no labeled panel

On October 28, 2026, HHS said it would not take enforcement action against 503A pharmacies and physicians compounding BPC-157, TB-500, Epitalon, Semax, KPV or MOTS-c under ten conditions, until each is settled by a final rule.^[5] None of the conditions involves a blood test. They cover the ingredient (tested, from an FDA-registered maker, with a full certificate of analysis), the product (one active peptide, specific routes, no delivery device other than an FDA-cleared syringe), the paperwork (a patient-specific prescription and a label reading “This is a compounded drug product. Not for resale.”), and reporting.^[5] The policy is interim, and it is not FDA approval. The overview of the HHS peptide policy covers each condition.

Without a label, no one has worked out from trial data which tests catch which problems at which point, because the trials that would show it have not been run. A baseline metabolic panel or blood count before starting BPC-157 can still be reasonable, especially for someone with liver disease or on a blood thinner. That is ordinary caution, and a normal result says nothing about what is in the vial. What is known about each peptide’s harms is in BPC-157 side effects, MOTS-c dosage and side effects and what peptide therapy is. If you already take a GLP-1 and are adding a peptide, peptides alongside a GLP-1 covers what changes.

What the policy does require: reporting to MedWatch

The monitoring HHS wrote into the policy is surveillance of the products. Under condition 5, a compounding pharmacy must report to FDA and to the states the products it makes, any serious adverse event in a patient “regardless of whether or not considered drug related,” and quality problems such as contamination or a product that fails its specifications. Those reports go to MedWatch, and the instructions for reporting a problem “should be detailed on the product labeling provided to the patient.”^[5]

• Product reports name the active ingredient and its strength, the original manufacturer with its facility identifier, and the dosage form and route.^[5]
• Single-ingredient products exist partly to make reports usable. HHS says attributing an event to one substance is “essential for meaningful safety surveillance and signal detection.”^[5]
• The policy can be pulled back. HHS may revisit it if “a safety signal or product quality issue arises.”^[5] Reports are how such a signal would appear.

HHS framed the policy as a way to move users off research-use-only peptides supplied by foreign manufacturers.^[5] The reporting rule binds the pharmacy, though. A patient who has a reaction does not have to wait for anyone else to file.

How to report a problem yourself

1. Get care first. Trouble breathing, swelling of the face or throat, chest pain or a spreading rash after an injection needs urgent treatment before any paperwork.
2. Decide whether it counts as serious. FDA treats an event as serious when it causes death, is life-threatening, leads to a hospital stay, causes disability or lasting damage, or causes a birth defect, and also when it is another important medical event that needs treatment to prevent one of those outcomes. An emergency visit without admission is judged against those outcomes.^[7] Less serious problems, and suspected quality problems with the product, can still be reported.^[6]
3. File with MedWatch. FDA’s online form is open to patients, and Form 3500B is the consumer version. FDA suggests taking the form to your doctor, who can add clinical detail, but your doctor is not required to report, and you can file yourself.^[6]
4. Include the product details. Give the peptide name, strength, the pharmacy or seller, the lot number on the label, and any blood results from before and after. A lab value from a baseline panel is most useful here, as evidence in a report.
5. Tell the pharmacy and the prescriber, since under the policy the pharmacy must report serious events too.^[5]

Red flags: the panel sold as proof of safety

Peptide clinics often bundle a large “longevity” or “optimization” panel with the first prescription. More tests can feel like more care. The evidence on broad direct-to-consumer panels points the other way. A 2026 analysis of 76 commercial wellness panels from 12 platforms classed 58.1% of the 191 distinct tests as low-value or likely to set off harmful follow-up. Nine tests, mostly tumor markers, were judged likely to trigger a cascade of biopsies, surgery or imaging. The largest panel would be expected to produce 9.8 false-positive results for each healthy person tested.^[12] A 2025 review in Clinical Chemistry warned that aggressive marketing of such testing can cause psychological, physical and financial harm and risks medicalizing healthy people.^[13]

• The panel is presented as what makes the peptide safe. A blood test cannot check the identity, purity or sterility of what is in the vial. For that, the policy relies on the supplier’s certificate of analysis for the ingredient.^[5] Our guide to reading a peptide certificate of analysis shows what one should contain.
• Every patient gets the same 50-plus markers whatever peptide is prescribed. A test with a reason is tied to a specific risk of the drug or the patient.
• Tumor markers or calcitonin appear in a screen of healthy people. The GLP-1 labels themselves warn about unnecessary procedures from routine calcitonin.^[2]
• No one says what happens if a result is abnormal. The tesamorelin label pairs each test with an action, such as considering stopping the drug.^[1] A panel without that plan is data collection.
• Results are read against the clinic’s “optimal” ranges rather than the lab’s reference ranges, and the fix offered is another product.
• Labs are required, but adverse-event reporting never comes up. Under the policy, a pharmacy compounding these peptides is expected to put reporting instructions on the patient’s labeling.^[5]

The useful questions to ask a prescriber are short. Which of these tests does a label or guideline call for, and which are your own choice? What will you do differently if a result comes back abnormal? And who reports a reaction to FDA, and how?

Common questions